Business
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT.
About this update from Greenlite Ventures, Inc.
[{"type":"text","content":"\n NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted business TV show, announces episode 591, airing on the Fox Business Network tonight, Monday, August 26, 2024, at 10:30 PM PT. New to The Street's 591st TV episode line-up features the following five (5) Corporate interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) David Luci, President/CEO. 2). \"Game Changers\" segment interview with Iagon's (CRYPTO: IAG) ($IAG) Dr. Navjit Dhaliwal, CEO. 3). \"Game Changers\" segment interview with GreenLite Ventures, Inc.'s (OTC: GRNL) ($GRNL) (No Limit Technology Holdings, Inc.) Rafael Groswirt, CEO 4). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTC: SGTM) ($SGTM) Tony Raynor, CEO and Founder. 5). \"Sekur Privacy & Sekur Security – The Weekly Hack” segment with internet privacy expert Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). Episode 591 From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) (\"Company\"), a late-stage biopharmaceutical Company that publicly trades on the NASDAQ market. ACXP is developing a new class of small molecular antibiotics for the most common life-threatening bacterial infections. Recently, the Company completed its FDA Phase 2 clinical trials on its Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Management is now meeting with the FDA regarding the steps necessary to complete the Phase 3 clinical trial on the drug. Concurrently, ACXP is meeting with the FDA on the drug manufacturing processes, which must meet the government's standards. Management remains confident that Ibezapolstat can be manufactured and inventoried before the conclusion of 2024. The United States Patent and Trademark Office (USPTO) has issued a patent because the drug can, in treated patients, maintain and restore microbiome bacteria. Most pharmaceuticals destroy the gut's microbiome bacteria, which is the major cause of diseases and reinfections, typically caused by competitor drugs for CDI. The issued patent remains valid until June 2042. The Company is working globally...